ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY

被引：0
|
作者：
Chang, Xiujuan [1 ]
Yu, Shumin [1 ,2 ]
Pang, Jianzhi [1 ]
Zhang, Wei [1 ]
Kong, Huifang [1 ]
Huang, Jiagan [1 ]
Zhang, Guojie [1 ]
Zhang, Huixin [1 ]
Gu, Yueyue [1 ,3 ]
Dong, Zheng [1 ]
Chen, Yan [1 ]
Yang, Bin [1 ]
Liu, Jingping [4 ]
Yang, Yongping [1 ]
Zeng, Zhen [1 ,2 ,3 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[2] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[3] Anhui Med Univ, Sch Clin Med 5, Hefei, Anhui, Peoples R China
[4] Elect Power Hosp Beijing, Beijing, Peoples R China
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4402
引用
下载
收藏
页码：S1305 / S1306
页数：2
相关论文
共 50 条
  • [1] The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma.
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Zhang, Jihai
    Dong, Zheng
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Yang, Yongping
    Zeng, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16152 - E16152
  • [2] Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
    Zou, Jixue
    Huang, Peixin
    Ge, Ningling
    Xu, Xin
    Wang, Yanhong
    Zhang, Lan
    Chen, Yi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1898 - 1906
  • [3] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
    Chang, Xiujuan
    Yu, Shumin
    Pang, Jianzhi
    Zhang, Wei
    Kong, Huifang
    Huang, Jiagan
    Zhang, Guojie
    Zhang, Huixin
    Gu, Yueyue
    Chen, Yan
    Yang, Bin
    Liu, Jingping
    Zeng, Zhen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 847 - 861
  • [5] Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Wu, Jia-Yi
    Yin, Zhen-Yu
    Bai, Yan-Nan
    Chen, Yu-Feng
    Zhou, Song-Qiang
    Wang, Shuang-Jia
    Zhou, Jian-Yin
    Li, Yi-Nan
    Qiu, Fu-Nan
    Li, Bin
    Yan, Mao-Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1233 - 1240
  • [6] Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
    Liu, Qingyan
    Li, Rong
    Li, Lingling
    Wang, Gaokun
    Ji, Shiyu
    Zheng, Xuan
    Jia, Xiaodong
    Tao, Haitao
    Hu, Yi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [7] Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
    Li, Q.
    Chen, M.
    Cao, M.
    Yuan, G.
    Hu, X.
    Dai, W.
    Zang, M.
    Cheng, X.
    Huang, J.
    Hou, J.
    Chen, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1310 - S1310
  • [8] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.
    Lee, I-Cheng
    Wu, Chi-Jung
    Chen, San-Chi
    Chao, Yee
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
    Xue-Feng Liu
    Xiao-Dong Zhu
    Long-Hai Feng
    Xiao-Long Li
    Bin Xu
    Kang-Shuai Li
    Nan Xiao
    Ming Lei
    Hui-Chuan Sun
    Zhao-You Tang
    Experimental Hematology & Oncology, 11
  • [10] Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
    Yi, Yong
    Sun, Bao-Ye
    Weng, Jia-Lei
    Zhou, Cheng
    Zhou, Chen-Hao
    Cai, Ming-Hao
    Zhang, Jing-Yun
    Gao, Hong
    Sun, Jian
    Zhou, Jian
    Fan, Jia
    Ren, Ning
    Qiu, Shuang-Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
12345